Compare URGN & ATLC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | URGN | ATLC |
|---|---|---|
| Founded | 2004 | 1996 |
| Country | United States | United States |
| Employees | N/A | 576 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2016 | N/A |
| Metric | URGN | ATLC |
|---|---|---|
| Price | $26.85 | $82.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $29.29 | ★ $90.00 |
| AVG Volume (30 Days) | ★ 727.7K | 91.0K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,128,000.00 | N/A |
| Revenue This Year | $129.09 | $477.21 |
| Revenue Next Year | $70.96 | $10.42 |
| P/E Ratio | ★ N/A | $9.74 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.64 | $45.74 |
| 52 Week High | $32.37 | $93.21 |
| Indicator | URGN | ATLC |
|---|---|---|
| Relative Strength Index (RSI) | 47.77 | 53.79 |
| Support Level | $18.55 | $51.15 |
| Resistance Level | $27.76 | $91.10 |
| Average True Range (ATR) | 1.46 | 4.35 |
| MACD | -0.56 | -0.86 |
| Stochastic Oscillator | 12.80 | 34.50 |
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
Atlanticus Holdings Corp is a financial technology company powering more inclusive financial solutions for Everyday Americans. It provides technology and other support services to lenders who offer an array of financial products and services to consumers. The company's products and services are reported through two reportable segments. Credit as a Service (CaaS) offers products including private label credit cards using the Fortiva and Curae brand names as well as merchant-associated brands and Auto Finance provides purchase and/or service loans secured by automobiles from or for, and also provides floor-plan financing for, a pre-qualified network of independent automotive dealers and automotive finance companies in the buy-here, pay-here used car business.